Table 13:
Multi-gene Pharmacogenomic Tests Considered
| Name of Test (Company) | Available in Canada? | Effectiveness (Studies Included in our Clinical Review)a | Cost | Feasibility Studies in Ontario? |
|---|---|---|---|---|
| GeneSight (Myriad) | Yes, in Ontario | Greden et al, 201957 Winner et al, 201365 Hall-Flavin et al, 201355 |
$2,500 CAD78 | Yes97,b |
| Genecept Assay (Dynacare) | Yes | Perlis et al, 202061 | $495 CAD21 | Unclear |
| Neuropharmagen Core (InSource Diagnostics) | Yes | Han et al, 201860 Perez et al, 201762 |
$400 USD21 | Unclear |
| NeuroIDgenetix (AltheaDx)c | No, in United States | Bradley et al, 201858 | $2,000 USD81 | No |
| CNSDose (cnsdose) | No, in Australia and United States | Singh et al, 201564 | $299 AUD98 | No |
a
Effectiveness: Clinical studies included in our clinical review examined test efficacy in reference case population. See details on included genes/alleles in the clinical review, Appendix 6, Table A4.
b
IMPACT (Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment) study, partially supported by the Ontario Ministry of Research and Innovation grant of $7 million, and matching funds from the Centre for Addiction and Mental Health (CAMH), totalling about $19.5 million (available at http://impact.camhx.ca/en/clinicians-study).
c
Also known as IDgenetix in our economic evidence review.